Literature DB >> 3393423

Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis.

R Janknegt1, M J Nube, H M Van den Hoogenband, H G Oldenhof, A Steenhoek, T B Vree.   

Abstract

The pharmacokinetics of methotrexate and its 7-hydroxy metabolite were studied in a patient undergoing continuous ambulatory peritoneal dialysis. A biphasic plasma-disappearance pattern of methotrexate was observed, with half-lives of 3.5 and 29 hours. The 7-hydroxy metabolite accumulated and showed a very slow rate of elimination, with an estimated final elimination half-life of over 120 hours. The mean peritoneal clearance rate of methotrexate was 0.13 l/h (range 0.05-0.20 l/h), dwell times significantly influenced the clearance rate. Strict monitoring of the methotrexate level, even after low doses, is necessary in continuous ambulatory peritoneal dialysis patients, to prevent serious bone marrow toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393423     DOI: 10.1007/bf01962684

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  5 in total

Review 1.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Low-dose methotrexate kinetics in arthritis.

Authors:  J Edelman; D F Biggs; F Jamali; A S Russell
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

Review 4.  Drug therapy in continuous ambulatory peritoneal dialysis patients.

Authors:  R Janknegt; J H Koelman
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

5.  Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M Martea; Y A Hekster; T B Vree; A J Voets; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24
  5 in total
  4 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.